REGENERON PHARMAC.DL-,001
REGENERON PHARMAC.DL-,001/ US75886F1075 /
RGO
|
12/11/2024 22:58:10
|
Diferencia
-3.60
|
Volumen |
Bid22:58:10 |
Ask22:58:10 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
772.00EUR
|
-0.46%
|
-
Volumen de negocios: - |
772.00Volumen de oferta: - |
773.60Tamaño/ Volumen/ Formato de Ask: - |
84.93 mil millonesEUR |
- |
- |
Descripción de negocio
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Consejo de gestión & Consejo de supervisión
| CEO |
| Dr. Leonard S. Schleifer |
| Consejo de gestión |
| Robert E. Landry, Dr. George D. Yancopoulos |
| Consejo de supervisión |
| Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D. |
Datos de la empresa
| Nombre: |
Regeneron Pharmaceuticals Inc. |
| Dirección: |
777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA |
| Teléfono: |
+1-914-847-7000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
is.gd/sEAmh8 |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
68.40% |
| Fecha de OPI: |
12/04/1991 |
Relación con inversores
| Nombre: |
- |
| IR teléfono: |
+1-914-847-7741 |
| IR-fax: |
- |
| IR e-mail: |
invest@regeneron.com
|
Accionistas mayoritarios
| Otros |
|
50.26% |
| FMR LLC. |
|
9.52% |
| Vanguard Group |
|
8.16% |
| BlackRock Inc. |
|
7.96% |
| JP Morgan Chase & Co. |
|
6.67% |
| Capital World Investors |
|
4.73% |
| State Street Corporation |
|
4.52% |
| Capital International Investors |
|
2.69% |
| Dodge & Cox |
|
2.18% |
| Otros |
|
3.30% |
